Kymera Therapeutics (KYMR) News Today $42.63 +1.08 (+2.60%) Closing price 04:00 PM EasternExtended Trading$42.84 +0.20 (+0.48%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is Kymera Therapeutics Up Today?Toggle Visibility of Why Is Kymera Therapeutics Up Today?Kymera Therapeutics, Inc. (NASDAQ: KYMR) saw its shares rise today on mixed analyst actions. Upward revisions to near-term earnings forecasts outweighed a cut to the full-year outlook. Positive Sentiment: B. Riley raised its Q3 2025 EPS estimate to ($0.98) from ($1.04), maintained a “Strong-Buy” rating and a $60.00 price target. B. Riley Expects Higher Earnings for Kymera Therapeutics Positive Sentiment: Brookline Capital Management boosted its Q3 2025 EPS forecast to ($0.86) from ($0.92) and raised multi-year earnings outlooks through 2029. MarketBeat Free Report Positive Sentiment: Leerink Partnrs increased its Q3 2025 EPS view to ($0.96) from ($1.12), while lifting Q4 2025 and FY2026 estimates. Q3 Earnings Forecast for KYMR Issued By Leerink Partnrs Neutral Sentiment: Leerink Partnrs forecast Q3 2026 EPS of ($1.09) and Q4 2026 EPS of ($1.11), aligning with consensus expectations. What is Leerink Partnrs' Estimate for KYMR Q3 Earnings? Negative Sentiment: HC Wainwright cut its FY2025 EPS forecast to ($3.26) from ($3.09), though it kept a “Buy” rating and a $60.00 target. HC Wainwright Cuts FY2025 EPS for Kymera Posted 3h agoAI Generated. May Contain Errors. KYMR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period What is Leerink Partnrs' Estimate for KYMR Q3 Earnings?August 15 at 9:36 AM | marketbeat.comB. Riley Expects Higher Earnings for Kymera TherapeuticsAugust 15 at 2:33 AM | americanbankingnews.comQ3 Earnings Forecast for KYMR Issued By Leerink PartnrsAugust 14 at 2:53 AM | americanbankingnews.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2025 Earnings Call TranscriptAugust 13 at 10:41 AM | msn.comKymera Therapeutics’ Earnings Call: Optimism and Strategic ProgressAugust 13 at 5:41 AM | msn.comKymera Therapeutics (NASDAQ:KYMR) Shares Gap Down on Disappointing EarningsAugust 12 at 10:31 AM | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Releases Earnings Results, Misses Expectations By $0.11 EPSAugust 12 at 7:35 AM | marketbeat.comKymera Therapeutics, Inc.: Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business UpdateAugust 12 at 2:19 AM | finanznachrichten.deKymera Revenue Drops 55 Percent in Q2August 12 at 2:19 AM | theglobeandmail.comKymera Therapeutics (NASDAQ:KYMR) Shares Gap Down Following Weak EarningsAugust 12 at 2:19 AM | americanbankingnews.comKymera Therapeutics Reports Q2 2025 Progress and PartnershipsAugust 11, 2025 | tipranks.comKymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call TranscriptAugust 11, 2025 | seekingalpha.comKymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business UpdateAugust 11, 2025 | globenewswire.comStocks With Rising Relative Price Strength: Kymera TherapeuticsAugust 6, 2025 | msn.comKymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025August 5, 2025 | finance.yahoo.comTD Asset Management Inc Sells 26,468 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)August 3, 2025 | marketbeat.comVictory Capital Management Inc. Cuts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)August 3, 2025 | marketbeat.comQ2 Earnings Estimate for KYMR Issued By B. RileyAugust 2, 2025 | marketbeat.comB. Riley Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR)July 31, 2025 | marketbeat.comKymera Therapeutics (KYMR) to Release Quarterly Earnings on WednesdayJuly 30, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Trims Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)July 30, 2025 | marketbeat.comNeo Ivy Capital Management Invests $395,000 in Kymera Therapeutics, Inc. (NASDAQ:KYMR)July 27, 2025 | marketbeat.comJennison Associates LLC Sells 164,647 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)July 21, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Upgraded at The Goldman Sachs GroupJuly 18, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from AnalystsJuly 17, 2025 | marketbeat.comKymera Therapeutics Inc (KYMR) - Investing.comJuly 11, 2025 | investing.comQ3 EPS Estimate for Kymera Therapeutics Raised by AnalystJuly 9, 2025 | marketbeat.comKymera Therapeutics (KYMR) director group buys $13.9 million in stockJuly 3, 2025 | investing.comKymera Therapeutics (NASDAQ:KYMR) Coverage Initiated at Morgan StanleyJuly 3, 2025 | marketbeat.comTuesday’s Insider Activity: Major Buys and Sells Shake Up MarketsJuly 3, 2025 | investing.comInsider Buying: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Buys 317,167 Shares of StockJuly 2, 2025 | insidertrades.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bvf Partners L. P/Il Purchases 317,167 SharesJuly 1, 2025 | marketbeat.comBros. Advisors Lp Baker Purchases 655,500 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) StockJuly 1, 2025 | insidertrades.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bros. Advisors Lp Baker Buys 655,500 SharesJune 30, 2025 | marketbeat.comHC Wainwright Has Strong Forecast for KYMR FY2026 EarningsJune 30, 2025 | marketbeat.comKYMR Q3 EPS Estimate Reduced by Brookline Capital ManagementJune 30, 2025 | marketbeat.comOppenheimer Cuts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $53.00June 27, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading Volume - Time to Buy?June 27, 2025 | marketbeat.comKymera Therapeutics Announces Pricing of $250 Million Public OfferingJune 26, 2025 | globenewswire.comKymera Therapeutics (NASDAQ:KYMR) Shares Down 4.1% Following Analyst DowngradeJune 26, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Price Target Lowered to $53.00 at Wells Fargo & CompanyJune 26, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 at HC WainwrightJune 26, 2025 | marketbeat.comKYMR Kymera Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comKymera signs $750M Gilead deal, announces $250M stock offeringJune 26, 2025 | bizjournals.comKymera Therapeutics Announces Proposed Public OfferingJune 25, 2025 | globenewswire.comKymera Therapeutics (NASDAQ:KYMR) Shares Gap Down - Time to Sell?June 25, 2025 | marketbeat.comKymera: Sanofi Ends KT-474 Work, Will Advance KT-485June 25, 2025 | marketwatch.comGilead Sciences, Kymera Therapeutics Set Cancer-Drug CollaborationJune 25, 2025 | marketwatch.comGilead signs up to $750 million cancer drug deal with Kymera TherapeuticsJune 25, 2025 | reuters.comKymera Therapeutics Announces Sanofi IRAK4 Collaboration UpdateJune 25, 2025 | globenewswire.com Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address KYMR Media Mentions By Week KYMR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYMR News Sentiment▼0.440.61▲Average Medical News Sentiment KYMR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYMR Articles This Week▼256▲KYMR Articles Average Week Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRNA News Today VRNA News Today BBIO News Today BPMC News Today ELAN News Today ROIV News Today GRFS News Today LEGN News Today RVMD News Today RYTM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYMR) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access